JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Asin, S.
Right arrow Articles by Paya, C. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Asin, S.
Right arrow Articles by Paya, C. V.

 Previous Article  |  Next Article 

Journal of Virology, May 1999, p. 3893-3903, Vol. 73, No. 5
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Ikappa kappa Mediates NF-kappa B Activation in Human Immunodeficiency Virus-Infected Cells

Susana Asin,1 Julie A. Taylor,1 Sergey Trushin,1 Gary Bren,1 and Carlos V. Paya1,2,*

Department of Immunology1 and Division of Infectious Diseases,2 Mayo Clinic, Rochester, Minnesota 55905

Received 16 September 1998/Accepted 27 January 1999


    ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Human monocytes and macrophages are persistent reservoirs of human immunodeficiency virus (HIV) type-1. Persistent HIV infection of these cells results in increased levels of NF-kappa B in the nucleus secondary to increased Ikappa Balpha , Ikappa Bbeta , and Ikappa Bvarepsilon degradation, a mechanism postulated to regulate viral persistence. To characterize the molecular mechanisms regulating HIV-mediated degradation of Ikappa B, we have sought to identify the regulatory domains of Ikappa Balpha targeted by HIV infection. Using monocytic cells stably expressing different transdominant molecules of Ikappa Balpha , we determined that persistent HIV infection of these cells targets the NH2 but not the COOH terminus of Ikappa Balpha . Further analysis demonstrated that phosphorylation at S32 and S36 is necessary for HIV-dependent Ikappa Balpha degradation and NF-kappa B activation. Of the putative N-terminal Ikappa Balpha kinases, we demonstrated that the Ikappa kappa complex, but not p90rsk, is activated by HIV infection and mediates HIV-dependent NF-kappa B activation. Analysis of viral replication in cells that constitutively express Ikappa Balpha negative transdominant molecules demonstrated a lack of correlation between virus-induced NF-kappa B (p65/p50) nuclear translocation and degree of viral persistence in human monocytes.


    INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

The Rel family of transcription factors plays an important role in the transactivation of several viral genes, including those of human immunodeficiency virus (HIV) type 1 (HIV-1) (25, 38). HIV-1 replication is regulated, in part, at the transcriptional level through the interplay of viral regulatory proteins with cellular transcription factors interacting with the viral long terminal repeat (LTR) (39). Since the identification and functional characterization of NF-kappa B cis-acting sequences within the HIV LTR (38), multiple studies have addressed the essential or dispensable role that this transcription factor plays in the reactivation of HIV from a true latent state and in the control of viral persistence (1, 10, 27, 31, 54, 55). Unfortunately, these studies have yielded conflicting results as to the role of NF-kappa B in these two steps of the viral life cycle in infected host cells. Differences in the type of host cells studied, HIV strain or genetic constructs used, and methodological approaches may explain these conflicting results.

Understanding the potential impact of NF-kappa B on the regulation of HIV latency has again become a priority, as recent studies suggest that NF-kappa B controls the reactivation of latent HIV in T cells from HIV-infected patients undergoing highly active antiretroviral therapy (19). An additional reservoir of HIV, separate from that of T cells harboring latent HIV, are cells of the monocyte lineage in which persistent viral replication is observed (36). During all stages of HIV infection, tissue macrophages provide a unique viral reservoir. In these cells, HIV persistently replicates in the absence of cytopathicity, escapes immune surveillance, and spreads via cell-to-cell contact (reviewed in reference 36). The important role of macrophages in AIDS pathogenesis has prompted the investigation of the molecular mechanisms which regulate HIV-1 persistence in these immune cells; one of these mechanisms is thought to be NF-kappa B dependent. Human macrophages express a constitutive level of NF-kappa B in the nuclei in the absence of exogenous cellular activation (25). This constitutive pool of nuclear NF-kappa B may be sufficient to allow for the initiation of HIV transcription immediately following infection. In addition, NF-kappa B may be required to further sustain persistent HIV replication, as multiple studies have demonstrated that persistent HIV replication in human macrophages or monocytes further upregulates NF-kappa B activity (2, 34, 40, 43, 48). However, the mechanisms by which HIV infection induces the activation of NF-kappa B in cells of the monocyte lineage remains unknown. Their identification would greatly enhance the understanding of this process and allow future testing of whether inhibition of the virus-induced activation of NF-kappa B may decrease viral persistence in cells of the monocyte lineage, hence eliminating an important reservoir of HIV replication in infected patients.

NF-kappa B is a heterodimeric protein composed of different combinations of members of the Rel family of transcription factors. A well-characterized form of NF-kappa B is a heterodimer of p50 and Rel-A (p65) (reviewed in references 3 and 4). In the majority of cells studied, NF-kappa B is anchored in the cytosol by an inhibitory protein, Ikappa B. An extensively studied Ikappa B molecule, Ikappa Balpha , has previously been shown to physically interact with NF-kappa B and to mask the nuclear localization signal of p50 and Rel-A (6). Following cell activation by one of an array of extracellular stimuli, Ikappa Balpha undergoes a hyperphosphorylation event that renders the inhibitory molecule susceptible to degradation (7, 13, 47). This process results in the release of NF-kappa B, which undergoes nuclear translocation and drives gene transcription. Significant advances in the understanding of the molecular mechanisms and the structure-function of the phosphorylation and degradation of Ikappa Balpha have recently been made. Ikappa Balpha is constitutively phosphorylated at its COOH terminus by protein kinase-casein kinase II (PK-CK2) (5, 33, 35, 45). While the exact function of this phosphorylation is poorly understood, it appears that phosphorylation at the COOH terminus may play a role in the constitutively rapid protein turnover of Ikappa Balpha in resting cells, thus potentially favoring a low degree of continuous NF-kappa B translocation. On the contrary, the N terminus contains two series (S32 and S36) which are required for stimulus-dependent phosphorylation (8, 9, 11, 15, 46, 49, 50, 52) by specific kinases, such as the ones present in the Ikappa kappa complex (Ikappa kappa alpha and Ikappa kappa beta ) or p90rsk (12, 16, 20, 24, 37, 42, 44, 53, 57). Phosphorylation at these sites primes Ikappa Balpha to undergo ubiquitination and subsequent degradation by the proteosome.

Our group has previously determined that a mechanism whereby HIV infection results in an increase in the nuclear translocation of NF-kappa B involves modification and enhancement of Ikappa Balpha turnover (34). The half-life of Ikappa Balpha in HIV-infected cells is reduced by at least 50% compared to that in uninfected cells, and this fact directly correlates with increased levels of the nuclear pool of NF-kappa B in HIV-infected cells. That Ikappa Balpha is the target of persistent HIV infection in monocytic cells has been further confirmed by other groups (14, 27); one of those groups further demonstrated that inhibition of Ikappa Balpha degradation with proteosome inhibitors decreases HIV-induced NF-kappa B activation (27). What remain to be elucidated are the molecular mechanisms whereby HIV infection targets Ikappa Balpha . Potential mechanisms regulated by HIV infection could target the COOH terminus of Ikappa Balpha , favoring an enhanced "basal" turnover of this inhibitor molecule by activating PK-CK2 or the proteolytic machinery. Alternatively, HIV infection could result in the activation of other Ikappa Balpha kinases that target S32 and S36, thus continuously priming Ikappa Balpha to be degraded via the proteosome. Lastly, HIV could target other regulatory sites of Ikappa Balpha or even other molecules, such as Rel-A, that could result in the dissociation of NF-kappa B from Ikappa Balpha , thus rendering Ikappa Balpha less stable.

To investigate these possibilities, we have used a cell model of monocytic cells in which persistent HIV replication results in NF-kappa B activation and a variety of genetically modified tagged Ikappa Balpha molecules can be constitutively overexpressed. Our results indicate that HIV infection targets the NH2 terminus of Ikappa Balpha , specifically S32 and S36, causing the enhanced degradation of Ikappa Balpha and hence increased NF-kappa B nuclear translocation. The Ikappa kappa complex kinase activity is selectively activated and is shown to mediate increased NF-kappa B activation in HIV-infected cells. In addition, we demonstrate that HIV-mediated NF-kappa B activation is not necessary to maintain viral persistence in monocytic cells.


    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Reagents and antibodies. Tumor necrosis factor (TNF) was purchased from Genzyme (Cambridge, Mass.) and stored in aliquots at -70°C. Cycloheximide was purchased from Sigma (St. Louis, Mo.) and stored at -20°C. Calpain inhibitor I (N-acetyl-Leu-Leu-norleucinal or ALLN) was purchased from Boehringer Mannheim Biochemicals (Indianapolis, Ind.), solubilized in ethyl alcohol, and stored in aliquots at -20°C. Bay 11-7082 (41) was purchased from Biomol (Plymouth Meeting, Pa.), solubilized in ethyl alcohol, and stored at -20°C. G418 was purchased from Calbiochem-Novabiochem Corporation (La Jolla, Calif.), solubilized in RPMI medium, and stored in aliquots at -20°C.

The expression of the Flag-tagged Ikappa B constructs was monitored with an anti-Flag monoclonal antibody (Kodak, New Haven, Conn.). To control for equal loading of proteins in sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) analysis, an anti-beta -actin polyclonal antibody (Sigma) and an anti-p90rsk antibody (Santa Cruz Biotechnology, Santa Cruz, Calif.) were used. Polyclonal anti-Ikappa Balpha serum was generated with a glutathione S-transferase (GST)-MAD3 fusion protein (34). The viral envelope protein gp120 was detected with an anti-gp120 polyclonal antibody (Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Md.). The identity of the complexes binding DNA in the gel shift assays was determined with polyclonal antibodies against the different members of the Rel family (Santa Cruz Biotechnology). Antibodies against p90rsk, Ikappa kappa alpha , Ikappa kappa beta , Raf-1, and NF-kappa B were purchased from Santa Cruz Biotechnology.

DNA constructs. pCMV2-FLAG-Ikappa Balpha -wt consisted of the full-length "wild-type" sequence of human Ikappa Balpha (26) cloned into the SmaI-HindIII sites of pCMV2FLAG (Kodak) to generate N-terminally Flag-tagged Ikappa Balpha -wt (Flag-Ikappa Balpha -wt). Flag-Ikappa Balpha -wt was used as a template for subsequent mutations and deletions by PCR-based techniques. Flag-Ikappa Balpha -Delta N consisted of an N-terminal deletion lacking the first 37 amino acids. This construct was generated with the sense primer wt-FLAG (5'CGGAATTCATGGACTACAAAGACGAT3') and the antisense primer wt-B (5'GGAATTCCTCATAACGTCAGACGCTG3'). EcoRI sites were created upstream and downstream of the coding sequence. Flag-Ikappa Balpha -Delta C consisted of a C-terminal deletion lacking the last 40 amino acids and was generated with the sense primer wt-FLAG and the antisense primer Delta C (5'GCGAATTCTCAAAGGTTTTCTAGTGTC3'). This construct contained an EcoRI site downstream of the coding sequence. Flag-Ikappa Balpha -2N consisted of the full-length sequence of Ikappa Balpha -wt in which S32 and S36 were mutated to alanine residues. To generate these mutations, a sense primer with the sequence 5'GACGCAGGCCTGGACGCAATG3' and an antisense primer with the sequence 5'CATTGCGTCCAGGCCTGCGTC3' were used. Flag-Ikappa Balpha -4C was created by mutation of S283, S288, S293, and T291 to alanine residues in the PEST sequence (35), cloning into the HindIII-EcoRI site of pCMV2FLAG, and then PCR amplifying with the sense primer wt-FLAG and the antisense primer wt-B. Flag-Ikappa Balpha -wt, Flag-Ikappa Balpha -Delta N, Flag-Ikappa Balpha -Delta C, Flag-Ikappa Balpha -2N, and Flag-Ikappa Balpha -4C were then digested and cloned into the EcoRI site of SFFV-Neo under the transcriptional regulation of the Friend spleen focus-forming virus (SFFV) 5' LTR (22). All of the cloning was verified by DNA sequencing.

Plasmid kappa B-luc contains three tandem copies of the kappa B motif of the HIV LTR cloned upstream of the minimal conalbumin-luciferase (con-luc) promoter reporter gene. Plasmid pBLCAT 2 is a mammalian reporter vector designed for the expression of chloramphenicol acetyltransferase (CAT) in mammalian cells transcribed by the minimal thymidine kinase (TK) promoter (Promega, Madison, Wis.). Plasmids Ikappa kappa alpha wt and kinase dead were kind gifts from Alain Israel, Institute Pasteur, Paris, France. Plasmids Ikappa kappa beta wt and kinase dead were obtained from M. Roth (Tularik, San Jose, Calif.). Ikappa kappa alpha kinase dead was generated by mutation of aspartic acid 144 to asparagine. Ikappa kappa beta kinase dead was created by mutation of lysine 44 to alanine. pcDNA3-Ikappa kappa expression vectors were generated by cloning the cDNA of wild-type Ikappa kappa alpha or Ikappa kappa beta or its respective mutant into the cytomegalovirus expression vector pcDNA3 (Invitrogen).

Gene transfection and generation of cell lines. The U937 promonocytic cell line was purchased from the American Type Culture Collection and grown in RPMI 1640 supplemented with 5% heat-inactivated fetal bovine serum (Intergen), 1% glutamine, and 1% penicillin-streptomycin. To generate Ikappa Balpha -expressing cell lines, 107 freshly thawed and exponentially growing U937 cells were resuspended in RPMI 1640 and electroporated with 20 µg of previously linearized DNA by use of a BTX cell electroporator at 250 V for 10 ms. U937 cells electroporated without DNA were used as controls. At 24 h after transfection, cells were resuspended in selection medium containing 5% fetal bovine serum and 700 µg of G418 per ml. After 3 to 4 weeks, upon the incipient growth of neomycin-resistant bulk cultures, cells were cloned by limiting dilution (30). Stable integration and expression of the transfected genes within each monoclonal population were verified by serial passages of the cultures in the absence of the selective antibiotic and by immunoblotting with anti-Flag antibodies.

Separate clones expressing equal levels of Flag-Ikappa Balpha constructs were selected, and their CD4 surface expression was verified by flow cytometry analysis. Thereafter, three clones expressing each of the Flag-Ikappa Balpha constructs were pooled, and exponentially growing cells were mock or HIV infected. The level of expression of each of the tagged Ikappa Balpha constructs was confirmed before and during the period of HIV infection by immunoblotting of cytosolic extracts with anti-Flag antibodies.

Transient transfection of U937 cells was performed as follows. A total of 107 exponentially growing U937 cells were incubated with 4 µg of the con-luc or kappa B-con-luc reporter construct, 6 µg of the pDNA3-Ikappa kappa construct, 4 µg of the pBLCAT2 reporter, and 300 µg of DEAE-dextran (Pharmacia, Piscataway, N.J.) per ml for 90 min at room temperature. Dimethyl sulfoxide (10%) was then added for 3 min, followed by extensive washing and plating at 0.5 × 107/cells/ml. Two days later, cells were harvested. Luciferase levels were measured with the Promega luciferase assay system, and CAT activity was measured with a CAT enzyme-linked immunosorbent assay kit (Boehringer).

HIV infection and measurement of HIV replication. U937 cells expressing SFFV, Flag-Ikappa Balpha -wt, Flag-Ikappa Balpha -Delta N, Flag-Ikappa Balpha -Delta C, Flag-Ikappa Balpha -2N, and Flag-Ikappa Balpha -4C were infected with the HIV LAV-Bru strain as previously described (2, 34, 40). Briefly, 107 exponentially growing U937 cells were sedimented by low-speed centrifugation and resuspended overnight in 10 ml of infective supernatant containing 360 ng of p24 per ml. Mock-infected cells were used as a control. After 24 h, cells were extensively washed and resuspended in culture medium. Cells were passaged twice a week at 0.25 × 106 cells/ml and used from day 30 through day 90 postinfection. During this period, cell supernatants were collected, precleared by centrifugation at 1,500 rpm for 5 min at 4°C, and stored for future analysis of HIV p24 antigen content by an enzyme-linked immunosorbent assay (Coulter-Immunotech Immunology, Westbrook, Maine). At least eight consecutive infections were used for each of these experiments. All the cell lines studied maintained HIV persistence and 100% viability during the study period, except for the U937 clones expressing Flag-Ikappa Balpha -Delta C, which maintained viability and normal growth while uninfected which underwent immediate and massive cytopathicity upon HIV infection in four consecutive attempts. Therefore, a U937 cell line expressing Flag-Ikappa Balpha -Delta C could not support a persistent HIV infection. In addition, in some experiments, HIV gp120 expression was determined by immunoblotting with anti-gp120 antibodies.

Nuclear and cytosolic extracts, electrophoretic mobility shift assays, and immunoblotting. Nuclear and cytosolic extracts were prepared by a modification of the method of Dignam et al. (17). A total of 107 cells were washed with ice-cold phosphate-buffered saline and then with buffer A (10 mM HEPES [pH 7.9], 1.5 mM MgCl2, 10 mM KCl). Cells were then lysed for 10 min on ice in the same buffer containing 0.1% Nonidet P-40, 0.5 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 2 µg of aprotinin per ml, 2 µg of leupeptin per ml, and 2 µg of pepstatin per ml. After centrifugation, cells were washed twice with buffer A. Nuclei were pelleted by centrifugation, lysed by resuspension in 25 µl of buffer C (20 mM HEPES, 25% glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, DTT, PMSF, aprotinin, leupeptin, pepstatin) and rotated at 4°C for 30 min. After centrifugation, the supernatants were diluted in 50 µl of buffer D (20 mM HEPES, 20% glycerol, 0.05 M KCl, 0.2 M EDTA, DTT, PMSF, aprotinin, leupeptin, pepstatin) and stored at -70°C.

For electrophoretic mobility shift assays, 6 µg of nuclear extract was incubated with a [gamma -32P]ATP-labeled double-stranded NF-kappa B oligonucleotide probe in 15 µl of DNA binding buffer for 15 min at room temperature as previously described (2, 34, 40). Components of the HIV-induced DNA binding protein complexes were identified by incubation of the extract with specific polyclonal antibodies against p50 and Rel-A prior to addition of the labeled probe. The resulting protein-DNA complexes were resolved on a 5% polyacrylamide gel and visualized by autoradiography.

To characterize the level of expression of the Flag-Ikappa Balpha constructs in uninfected and infected cells, 40 µg of cytosolic protein was analyzed by SDS-10% PAGE. Proteins were transferred to Immobilon-P membranes (Millipore) by standard procedures and blotted with an anti-Flag monoclonal antibody, followed by incubation with rabbit anti-mouse immunoglobulin G (Pierce) and then horseradish peroxidase (Amersham, Buckinghamshire, England). Immunoreactive proteins were detected with an ECL Western blotting detection kit (Amersham). beta -Actin and p90rsk were used as internal controls for equal loading in all experiments.

Preparation of recombinant Ikappa Balpha . The Ikappa Balpha -MAD3 cDNA (26) plasmid was obtained from Cetus Corporation and was used as a template for subsequent PCR amplification.

The amino-terminal Ikappa Balpha -MAD3 (positions 1 to 54) sequence was amplified with wild-type primer A (5'CGGGATCCATGTTCCAGGCGGCCGAG3') as the sense primer, creating a BamHI site upstream of the coding sequence, and wild-type primer B (5'GGAATTCCTCAGCGGATCTCCTGCAGCT3') as the antisense primer, creating an EcoRI site downstream of the coding sequence. An S32/36A double mutant was amplified from the full-length cDNA by use of primers to create alanines at S32 and S36. Following digestion with BamHI-EcoRI, these sequences were ligated into pGEX-KG (derived from pGEX-2T, from Pharmacia, Piscataway, N.J.). These constructs were transformed into Escherichia coli DH5alpha cells, which were grown exponentially. After 60 min of stimulation with isopropylthiogalactopyranoside (Sigma), cells were lysed. Proteins were isolated by affinity chromatography on glutathione-bonded 4% cross-linked agarose (Sigma). The purity of GST-Ikappa Balpha (positions 1 to 54) containing the first 54 amino acids of Ikappa Balpha and GST-Ikappa Balpha (positions 1 to 54) containing S32/36A was analyzed by SDS-10% PAGE and subsequent Coomassie blue staining. The purity of both proteins was greater than 90%.

Immunoprecipitation of Ikappa Balpha kinases and in vitro kinase assays. Whole-cell extracts were prepared for immunoprecipitation and in vitro kinase assays as follows. Aliquots of 107 exponentially growing U937 cells were washed twice with cold phosphate-buffered saline, resuspended in lysis buffer containing 40 mM Tris-HCl (pH 8), 0.3 M NaCl, 0.1% Nonidet P-40, 6 mM EDTA, 6 mM EGTA, 10 mM NaF, 10 mM p-nitrophenyl phosphate (PNPP), 10 mM beta -glycerolphosphate, 300 µM sodium orthovanadate, 1 mM DDT, 2 µM PMSF, 10 µg of aprotinin per ml, 1 µg of leupeptin per ml, and 1 µg of pepstatin per ml, and incubated on ice. Cells were then centrifuged at 12,000 × g for 15 min at 4°C. The resultant supernatant contained total cellular proteins, which were quantitated with a Bio-Rad protein assay.

For immunoprecipitation of the Ikappa kappa complex, p90rsk, or Raf-1, 100 µg of cell extract was incubated with anti-Ikappa kappa alpha , anti-Ikappa kappa beta , anti-p90rsk, or anti-Raf-1 antibodies for 1 h at 4°C, after which protein A-agarose beads (Life Technologies, Gaithersburg, Md.) were added for 1 h. The beads were then washed three times with 0.5 M NaCl-based lysis buffer, followed by one wash with a buffer containing 50 mM Tris-HCl (pH 7.4) and 40 mM NaCl. The washed beads were then incubated in 15 µl of kinase buffer (20 mM HEPES [pH 7.4], 2 mM MgCl, 2 mM MnCl, 10 µM ATP, 10 mM NaF, 10 mM PNPP, 10 mM beta -glycerolphosphate, 300 µM sodium orthovanadate, 2 µM PMSF, 10 µg of aprotinin per ml, 1 µg of leupeptin per ml, 1 µg of pepstatin per ml, 1 mM DTT) with 2 µg of GST-Ikappa Balpha (positions 1 to 54) or GST-Ikappa Balpha (positions 1 to 54) containing S32/36A and 0.1 µCi of [gamma -32P]ATP. The kinase reaction was performed for 30 min at 30°C, and samples were resolved by SDS-PAGE, transferred to Immobilon-P membranes, and exposed to film.


    RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Increased degradation of Flag-Ikappa Balpha -wt in HIV-infected cells. To confirm the expression and functionality of the Flag-Ikappa Balpha constructs, pooled clones expressing equal levels of Flag-Ikappa B constructs were treated or not treated with TNF, followed by the analysis of the cytosolic extracts by SDS-PAGE and immunoblotting with anti-Flag antibodies. As shown in Fig. 1A, TNF stimulation led to the rapid hyperphosphorylation and subsequent degradation of Flag-Ikappa Balpha -wt. In contrast, Flag-Ikappa Balpha -Delta N and Flag-Ikappa Balpha -2N were refractory to TNF-induced hyperphosphorylation and subsequent degradation. Flag-Ikappa Balpha -4C behaved similarly to Flag-Ikappa Balpha -wt in that it was susceptible to TNF-mediated hyperphosphorylation and degradation. These results confirm that the constitutively overexpressed Flag-Ikappa Balpha molecules are regulated as previously described for native Ikappa Balpha and highlight the functional relevance of the N terminus containing S32 and S36 in TNF-induced Ikappa Balpha hyperphosphorylation and degradation.


View larger version (24K):
[in this window]
[in a new window]
 
FIG. 1.   Functional characterization of Flag-Ikappa Balpha molecules in U937 cells. (A) Pooled clones of U937 cells expressing the different Flag-Ikappa Balpha constructs were stimulated with TNF for different time periods, and the cell lysates were analyzed by immunoblotting with anti-Flag antibodies. The hyperphosphorylated form of Ikappa Balpha is indicated by a small circle. (B) Immunoblotting of cell lysates from mock-infected (NI) or HIV-infected (HIV), SFFV-expressing U937 cells with anti-Ikappa Balpha , anti-Ikappa Bbeta , anti-Ikappa Bvarepsilon , and antiactin antibodies. The hyperphosphorylated form of Ikappa Bvarepsilon is indicated by a small circle. (C) Immunoblotting of cell lysates from mock-infected (NI) or HIV-infected (HIV), SFFV- or Flag-Ikappa Balpha -wt-expressing U937 cells with anti-Flag and antiactin antibodies. (D) The half-life of Flag-Ikappa Balpha -wt was estimated by immunoblotting of cell lysates from mock-infected (NI) or HIV-infected (HIV), Flag-Ikappa Balpha -wt-expressing U937 cells treated with cycloheximide (CHX) for different periods of time with anti-Flag antibodies. Equal protein loading was calculated by immunoblotting the same membrane with anti-p90rsk antibody. (E) The half-life of Flag-Ikappa Balpha -wt was calculated by measuring with a densitometer the disintegrations per minute of Flag-Ikappa Balpha -wt and normalizing them to those for p90rsk from each experimental time point shown in panel D.

As expected (34), persistent HIV infection of U937 cells resulted in decreased cytosolic levels of native Ikappa Balpha . Moreover, Ikappa Bbeta and Ikappa Bvarepsilon protein levels were also significantly decreased in HIV-infected cells compared to uninfected cells (Fig. 1B).

Having determined that overexpressed Flag-Ikappa Balpha constructs function similarly to native Ikappa Balpha upon stimulation with known inducers of NF-kappa B and that HIV infection of U937 cells results in decreased steady-state levels of endogenous Ikappa B, we next investigated whether Flag-Ikappa Balpha -wt is also a target of HIV infection. Immunoblotting of cytosolic fractions from mock- and HIV-infected cells expressing Flag-Ikappa Balpha -wt was performed with anti-Flag antibodies. U937 cells transfected with the parental empty retrovirus vector (SFFV) were also mock or HIV infected and used as controls. As shown in Fig. 1C, the steady-state protein levels of Flag-Ikappa Balpha -wt were decreased in the cytosolic fractions of HIV-infected cells compared to mock-infected cells, confirming that HIV infection decreases the cytosolic levels of Flag-Ikappa Balpha and indicating that tagged Ikappa Balpha constructs can be used to study the regulatory domain(s) targeted by persistent HIV infection in monocytes.

Having previously demonstrated that the decreased level of native Ikappa Balpha is a result of the enhanced rate of Ikappa Balpha degradation in persistently HIV-infected monocytes, we investigated whether this process also accounted for the decreased level of Flag-Ikappa Balpha -wt in infected cells. The half-life of Flag-Ikappa Balpha -wt was estimated by immunoblotting Flag-Ikappa Balpha -wt from cytosolic fractions from mock- and HIV-infected cells treated for different time periods with cycloheximide. As shown in Fig. 1D, the turnover of Flag-Ikappa Balpha -wt was increased in HIV-infected cells compared to mock-infected cells. The half-lives of Flag-Ikappa Balpha -wt calculated from Fig. 1D were found to be approximately 60 min in HIV-infected cells and 128 min in uninfected cells (Fig. 1E).

The NH2 terminus but not the PEST sequence present in the COOH terminus of Ikappa Balpha is necessary for Ikappa Balpha degradation by HIV infection. To characterize which of the regulatory domains of Ikappa Balpha is targeted by HIV infection, we first focused on the NH2-terminal domain of Ikappa Balpha . We analyzed the turnover and half-life of Flag-Ikappa Balpha -Delta N. U937 cells stably transfected with the empty retrovirus vector (SFFV), Flag-Ikappa Balpha -wt, or Flag-Ikappa Balpha -Delta N were mock or HIV infected. The half-lives of these constructs were measured by analyzing the levels of the Flag-Ikappa Balpha constructs in cytosolic extracts from cell cultures treated for different time periods with cycloheximide (as for Fig. 1). As shown in Fig. 2A, Flag-Ikappa Balpha -Delta N was very stable not only in mock-infected but also in HIV-infected U937 cells, with the resulting half-lives being estimated at greater than 4 h (Fig. 2B). The enhanced stability of Flag-Ikappa Balpha -Delta N in both mock- and HIV-infected cells contrasts with the more rapid turnover of Flag-Ikappa Balpha -wt in mock-infected cells and even more rapid turnover in HIV-infected cells (Fig. 1D and Fig. 2A). These results indicate that the increased degradation of Ikappa Balpha that ensues in HIV-infected cells appears to be dependent on the NH2-terminal domain of the molecule. In addition, these results highlight the potential relevance of this Ikappa Balpha domain in the regulation of the basal turnover of Ikappa Balpha in unstimulated transformed cells.


View larger version (18K):
[in this window]
[in a new window]
 
FIG. 2.   Deletion of the first 37 amino acids of Ikappa Balpha conveys resistance to HIV-mediated degradation. (A) Mock-infected (NI) or HIV-infected (HIV), Flag-Ikappa Balpha -Delta N-expressing U937 cells were treated with cycloheximide (CHX) for different time periods, after which cell lysates were analyzed by immunoblotting with anti-Flag or antiactin antibodies. (B) The half-life of Flag-Ikappa Balpha -Delta N was calculated as described in the legend to Fig. 1E.

Previous studies have demonstrated that mutation of S283, S288, T291, and S293 to alanines eliminates the constitutive phosphorylation of Ikappa Balpha mediated by PK-CK2 and may influence the turnover of Ikappa Balpha (5, 33, 35, 45). Based on this information, we analyzed the turnover and half-life of Flag-Ikappa Balpha -4C in mock- or HIV-infected U937 cells and compared them to those of Flag-Ikappa Balpha -wt. In mock-infected U937 cells, the basal turnover of Flag-Ikappa Balpha -4C was slightly longer than that of Flag-Ikappa Balpha -wt (Fig. 3), suggesting a potential role of the C-terminal amino acids S283, S288, T291, and S293 in the basal turnover of Ikappa Balpha in unstimulated monocytic cells. The half-life of Flag-Ikappa Balpha -4C was shorter in HIV-infected cells than in mock-infected cells but was similar to the half-life of Flag-Ikappa Balpha -wt in HIV-infected cells (Fig. 3). These results demonstrate that the amino acids present in the PEST sequence of Ikappa Balpha are not involved in the HIV-mediated degradation and turnover of Ikappa Balpha .


View larger version (30K):
[in this window]
[in a new window]
 
FIG. 3.   Mutation of the phosphoamino acids present in the PEST sequence does not alter the HIV-mediated degradation of Ikappa Balpha . (A) Mock-infected (NI) or HIV-infected (HIV), Flag-Ikappa Balpha -4C- or Flag-Ikappa Balpha -wt-expressing U937 cells were treated for different time periods with cycloheximide (CHX), and cell lysates were analyzed by immunoblotting with anti-Flag and anti-p90rsk antibodies. The lysates used for detecting p90rsk levels were the same as those from Flag-Ikappa Balpha -4C-expressing U937 cells. Similar results were obtained with Flag-Ikappa Balpha -wt-expressing U937 cell lysates. (B) The half-lives of Flag-Ikappa Balpha -4C (left panel) and Flag-Ikappa Balpha -wt (right panel) were calculated as described in the legend to Fig. 1E.

HIV-induced degradation of Flag-Ikappa Balpha requires phosphorylation at the NH2-terminal residues S32 and S36. Several studies have identified S32 and S36 as targets of inducible Ikappa Balpha kinases (8, 9, 11, 15, 46, 49, 50, 52). As shown in Fig. 1A, mutation of S32 and S36 to alanines yields an Ikappa Balpha construct that is refractory to the hyperphosphorylation and subsequent degradation triggered by TNF in U937 cells. Having identified the NH2-terminal domain of Ikappa Balpha as a target of HIV-induced degradation, we next questioned whether S32 and S36 could be the amino acids that are targeted by HIV infection. For this, we investigated the half-life and turnover of Flag-Ikappa Balpha -2N in mock- and HIV-infected U937 cells and compared them to the half-life and turnover of Flag-Ikappa Balpha -wt. Following the same experimental design as that used for Fig. 2 and 3, we observed that in mock-infected cells, mutation of S32 and S36 to alanines significantly prolonged the half-life of Ikappa Balpha (greater than 5 h) compared to the more rapid turnover of Flag-Ikappa Balpha -wt (Fig. 4). This very low rate of basal degradation of Flag-Ikappa Balpha -2N is similar to that observed for Flag-Ikappa Balpha -Delta N (Fig. 2). Relevant to the focus of this study, we demonstrate that the half-life of Flag-Ikappa Balpha -wt is significantly reduced in HIV-infected cells compared to mock-infected cells and that Flag-Ikappa Balpha -2N was refractory to HIV-mediated Ikappa Balpha degradation (Fig. 4). These results confirm that S32 and S36 are the Ikappa Balpha amino acids targeted by persistent HIV infection to result in enhanced degradation of Ikappa Balpha .


View larger version (32K):
[in this window]
[in a new window]
 
FIG. 4.   Mutation of S32 and S36 of Ikappa Balpha abrogates HIV-mediated Ikappa Balpha degradation. (A) Mock-infected (NI) or HIV-infected (HIV), Flag-Ikappa Balpha -2N- or Flag-Ikappa Balpha -wt-expressing U937 cells were treated with cycloheximide (CHX) for different time periods, after which cell lysates were analyzed by SDS-PAGE and immunoblotted with anti-Flag and anti-p90rsk antibodies. The p90rsk lysates were the same as those from Flag-Ikappa Balpha -2N-expressing U937 cells. Similar results were obtained with Flag-Ikappa Balpha -wt-expressing U937 cell lysates. (B) The half-lives of Flag-Ikappa Balpha -2N and Flag-Ikappa Balpha -wt were calculated as described in the legend to Fig. 1E.

S32 and S36 are the targets of Ikappa Balpha kinases that are activated by a variety of stimuli, such as inflammatory cytokines, and phosphorylation at these amino acids renders Ikappa Balpha susceptible to degradation by the proteosome (8, 9, 11, 12, 15, 16, 24, 29, 37, 42, 43, 46, 49, 50, 52, 53, 57). To investigate whether HIV infection results in the hyperphosphorylation of Ikappa Balpha , mock- or HIV-infected U937 cells expressing Flag-Ikappa Balpha -wt were treated with the proteosome inhibitor ALLN for 3 h, after which cytosolic extracts were separated by SDS-PAGE and immunoblotted with anti-Flag antibodies. To control for the accurate detection of hyperphosphorylated Ikappa Balpha , mock-infected Flag-Ikappa Balpha -wt-expressing U937 cells were treated or not treated with TNF and/or a pharmacological inhibitor previously shown to inhibit the TNF-induced hyperphosphorylation of Ikappa Balpha (Bay 11-7082) (41). As shown in Fig. 5 (upper panel), a more slowly migrating form of Flag-Ikappa Balpha -wt was observed in mock-infected, TNF-treated cells, specifically in the presence of ALLN (lanes 3 and 4). In HIV-infected Flag-Ikappa Balpha -wt-expressing U937 cells, a more slowly migrating form of Flag-Ikappa Balpha -wt was observed only when ALLN was used (compare lanes 6 with lane 5). These effects are dependent on the presence of S32 and S36 in the Flag-Ikappa Balpha construct, as their mutation to alanines abrogated both TNF-induced and HIV-dependent Ikappa Balpha hyperphosphorylation (Fig. 5, lower panel). Altogether, these results indicate that the enhanced degradation of Ikappa Balpha that is observed in HIV-infected monocytes is a result of specific hyperphosphorylation of Ikappa Balpha at S32 and S36. Whether the differences in the kinetics of Ikappa Balpha hyperphosphorylation at S32 and S36 between transient stimuli, such as TNF, and chronic stimuli, such as persistent HIV infection, are due to the use of different Ikappa Balpha kinases or simply different upstream control mechanisms is currently unknown.


View larger version (28K):
[in this window]
[in a new window]
 
FIG. 5.   HIV infection of U937 cells induces hyperphosphorylation of Ikappa Balpha which is dependent on S32 and S36. Mock-infected (NI) or HIV-infected (HIV), Flag-Ikappa Balpha -wt- or Flag-Ikappa Balpha -2N-expressing U937 cells were treated (+) or not treated (-) with Bay 11-7082 (Bay 11), TNF, or ALLN, after which the cell lysates were analyzed by SDS-PAGE and immunoblotted with anti-Flag antibodies. The supershifted hyperphosphorylated Ikappa Balpha form of Flag-Ikappa Balpha -wt is indicated by a bullet.

The Ikappa kappa complex mediates HIV-dependent Ikappa Balpha degradation and NF-kappa B activation. Two kinases in the Ikappa kappa complex (Ikappa kappa alpha and Ikappa kappa beta ) have recently been shown to phosphorylate S32 and S36 of Ikappa Balpha and to be the targets of inflammatory cytokines, such as TNF and interleukin 1 (12, 16, 29, 37, 42, 53, 57). Having identified S32 and S36 as the regulatory amino acids of Ikappa Balpha which are targeted by HIV, we questioned whether the Ikappa kappa complex is activated by HIV infection and mediates the increased levels of nuclear NF-kappa B activation in infected cells. Mock-infected and persistently HIV-infected U937 cells were lysed, followed by immunoprecipitation of the Ikappa kappa complex, p90rsk, or Raf-1. The kinase activities of these immunoprecipitates were analyzed in an in vitro kinase reaction with GST-Ikappa Balpha (positions 1 to 54) or GST-Ikappa Balpha (positions 1 to 54) containing S32/36A as a substrate. In HIV-infected samples, increased Ikappa Balpha kinase activity was present in the Ikappa kappa complex immunoprecipitate but not in the p90rsk (Fig. 6A) or the Raf-1 (data not shown) immunoprecipitate. This kinase activity was specific for S32 and S36, as their mutation eliminated the basal and HIV-induced Ikappa kappa complex activity. Also, as shown in Fig. 6A, there was no difference in the amounts of Ikappa kappa complex immunoprecipitated with anti-Ikappa kappa alpha antibodies in mock- and HIV-infected U937 cells, thus eliminating the possibility that HIV infection simply increases the pool of Ikappa kappa kinases. These data indicate that HIV infection activates the Ikappa kappa complex, resulting in phosphorylation at S32 and S36.


View larger version (25K):
[in this window]
[in a new window]
 
FIG. 6.   The Ikappa kappa complex but not p90rsk mediates the HIV-induced activation of NF-kappa B. (A) In vitro kinase assay of Ikappa kappa and p90rsk. Immunoprecipitates (IP) from mock-infected (NI), mock-infected and TNF treated (TNF), and HIV-infected (HIV), SFFV-expressing U937 cells were lysed, and the Ikappa kappa complex and p90rsk were immunoprecipitated with anti-Ikappa kappa alpha and anti-p90rsk antibodies, respectively. Immunoprecipitates were analyzed in an in vitro kinase (IVK) assay with recombinant protein Ikappa Balpha -wt (positions 1 to 54) or Ikappa Balpha S32/36A (positions 1 to 54) as a substrate (32P-Ikappa Balpha ). The membrane was subsequently stained with Coomassie blue (stained Ikappa Balpha ) or immunoblotted (Immunoblot) with anti-Ikappa kappa alpha , anti-Ikappa kappa beta , or anti-p90rsk antibodies. (B) SFFV-expressing, HIV-infected U937 cells were transiently transfected with con-luc () or kappa B-con-luc () together with expression vectors for wild-type (WT) or negative dominant (nd) forms of Ikappa kappa alpha or Ikappa kappa beta and a TK CAT reporter gene. Luciferase units were normalized to CAT units. The NF-kappa B luciferase activity of uninfected, SFFV-expressing cells was similar to that of con-luc in HIV-infected cells, and none of the Ikappa kappa alpha or Ikappa kappa beta (wt or nd) expression vectors modified the basal level of plasmid kappa B-luc activity in uninfected cells (data not shown). This experiment is representative of three additional ones. Each transfection point was determined in duplicate, and error bars indicate ± standard deviations.

The potential relevance of the Ikappa kappa complex in mediating the HIV-dependent activation of NF-kappa B was further analyzed in transient transfection experiments. Transcription from an NF-kappa B-dependent luciferase reporter gene was analyzed with both mock- and HIV-infected U937 cells in the presence or absence of wild-type or dominant negative forms of Ikappa kappa alpha and Ikappa kappa beta . A minimal TK promoter driving the expression of CAT was used to normalize for transfection efficiency differences that might be present between mock- and HIV-infected cells. The results of these experiments demonstrated that the increased NF-kappa B activity that is observed in HIV-infected cells is reduced by an Ikappa kappa beta dominant negative expression vector but not by a dominant negative form of Ikappa kappa alpha or the wild-type form of either kinase (Fig. 6B). Altogether, these studies demonstrate that the Ikappa kappa complex is activated by HIV infection and mediates virus-induced Ikappa Balpha hyperphosphorylation and NF-kappa B activation.

HIV-1 replication in U937 cells expressing different transdominant mutants of Ikappa Balpha . Having determined that S32 and S36 of Ikappa Balpha are required for HIV-mediated Ikappa Balpha degradation, we next questioned whether U937 cells expressing Flag-Ikappa Balpha -Delta N or Flag-Ikappa Balpha -2N (constructs that are refractory to HIV-dependent degradation) would inhibit HIV-mediated NF-kappa B activation, and if so, whether this inhibition would result in decreased viral replication. Nuclear extracts and cell-free supernatants were obtained from mock- or HIV-infected cells stably transfected with the SFFV vector, Flag-Ikappa Balpha -Delta N or Flag-Ikappa Balpha -2N at the same time as the cytosolic fractions were analyzed to determine the half-lives of the respective Ikappa Balpha constructs (Fig. 2 and 4). Nuclear extracts were analyzed by a gel shift assay with an oligonucleotide containing NF-kappa B DNA binding motifs, and viral replication was monitored by measuring p24 levels in culture supernatants. As shown in Fig. 7A and B, left panels, HIV infection of SFFV-expressing U937 cells led to nuclear translocation of a DNA binding protein complex composed of p50 and Rel-A (p65); this finding was not observed in HIV-infected cells expressing either Flag-Ikappa Balpha -Delta N or Flag-Ikappa Balpha -2N (Fig. 7A and B, right panels). These observations directly correlate with the inability of these two Flag-Ikappa Balpha constructs to undergo HIV-mediated degradation, as demonstrated in Fig. 2 and 4.


View larger version (28K):
[in this window]
[in a new window]
 
FIG. 7.   Genetic interference with HIV-mediated NF-kappa B activation does not result in reduced HIV replication. (A) Gel shift assays of nuclear extracts from mock-infected (NI) or HIV-infected (HIV), SFFV- or Flag-Ikappa Balpha -Delta N-expressing U937 cells. Antibodies against p50 (p50) or p65 (p65) were added to the gel shift assay. The corresponding molecular complex is indicated. (B) Same panel A, except that nuclear extracts from SFFV-expressing U937 cells were compared in parallel to those from Flag-Ikappa Balpha -Delta -2N-expressing U937 cells. (C) The HIV p24 content in supernatants of HIV-infected, SFFV-expressing U937 cells () or cells expressing Flag-Ikappa Balpha -Delta N () and Flag-Ikappa Balpha -2N () was calculated in duplicate. This experiment is representative of two additional ones. Error bars indicate standard deviations.

The levels of HIV replication in the cells expressing SFFV, Flag-Ikappa Balpha -Delta N, or Flag-Ikappa Balpha -2N were then analyzed by measuring HIV p24 levels in supernatants from the same cultures as those used to study the Ikappa Balpha half-life (Fig. 2 and 4) and NF-kappa B nuclear translocation (Fig. 7A and B). The results of these experiments indicated that there was no significant reduction in the levels of p24 in supernatants of U937 cells expressing Flag-Ikappa Balpha -Delta N or Flag-Ikappa Balpha -2N compared to supernatants of control cultures (SFFV expressing) (Fig. 7C).


    DISCUSSION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References

Using an HIV-susceptible promonocytic cell line which can support persistent viral replication, we have determined that the Ikappa Balpha residues S32 and S36 and the Ikappa kappa complex (12, 16, 29, 37, 42, 53, 57) are required to mediate HIV-dependent Ikappa Balpha degradation and, hence, NF-kappa B activation. The identification of a transdominant negative Ikappa Balpha molecule which is refractory to HIV-dependent degradation and thus is capable of blocking the HIV-mediated activation of NF-kappa B extends and confirms previous studies from our group indicating that Ikappa Balpha is a target molecule and that persistent HIV infection leads to increased NF-kappa B activation (34). In addition, it provides supporting data that HIV-mediated NF-kappa B (p50/p65) activation is not necessary to support viral persistence in the U937 monocytic cell line.

The use of pooled clones of monocytic cells that constitutively express genetically modified Ikappa Balpha constructs has proven to be a valuable tool with which to study the role of NF-kappa B replication in HIV persistence. Different from punctual stimuli (inflammatory cytokines or transient expression of human T-cell leukemia virus type 1 tax), the activation of NF-kappa B by HIV infection is dependent on the establishment of viral persistence, achieved only after 6 to 10 days of viral infection (2, 34, 40). Due to this unique virus-host cell interaction, the experimental approaches which can be utilized to address the mechanisms by which HIV activates NF-kappa B have been significantly limited. Previous attempts have used nonmonocytic cell lines which a